

REVIEW

Open Access



The role of viral infection in implantation failure: direct and indirect effects

Marzieh Rezaei¹ and Mohsen Moghoofoei^{2,3*} 

Abstract

Implantation is the key initial complex stage of pregnancy. Several factors are involved in implantation, but acute and controlled inflammation has been shown to play as a key role. On the other hand, the role of viral infections in directly infecting blastocyst and trophoblast and inducing chronic and uncontrolled inflammation and disrupting microRNAs expression can make this review strongly attractive and practical. We aim to provide an overview of viral infections as the potential etiology of unsuccessful implantation pathophysiology through alteration of the cellular and molecular endometrial microenvironment. Based on our search, this is the first review to discuss the role of inflammation associated with viral infection in implantation failure.

Keywords Implantation, Virus, Inflammation, Infection

Introduction

Implantation or nidation is an initial complex stage in which the blastocyst burrows into the endometrium of the female's uterine wall and, if successful, the female is considered pregnant [1, 2]. Apposition, adhesion and penetration are the three main stages of implantation. Apposition occurs when the blastocyst is unstably attached to the endometrial surface. The next stage is adhesion as the association of the luminal epithelium with the trophoblast and the resistance of the blastocyst to displacement by lavage of the uterine lumen [3, 4]. Stromal vascular permeability is increased (localized) at the blastocyst attachment site and is considered the first sign of attachment [3].

The last stage is penetration, so that the stroma is invaded by the embryo through the epithelium to access the maternal vasculature. Trophoblasts and the decidua control and limit the extent of invasion [3, 4]. Because the embryo is different from the mother's cells, it may be considered a pathogen by the mother's immune system if it does not secrete immunosuppressive agents [5, 6]. Many factors are involved in proper embryo implantation and uterine receptivity to modulate endometrial functions. These include cytokines, chemokines, and growth factors [7]. The uterus-embryo cross talk triggers changes in the endometrium, which is critical to the receptivity of the uterus [8]. There is a negative human chorionic gonadotropin (hCG) test in urine or blood during implantation [9]. Failure of the implantation process is one of the most common causes of female infertility. Recurrent Implant Failure (RIF) is a clinical condition in which good quality embryos fail to implant in the uterus after multiple in vitro fertilization (IVF) attempts [9, 10]. Several mechanisms are involved in implantation failure, including leiomyoma, endometriosis, polycystic ovarian syndrome (PCOS), hydrosalpinx, and exposure to toxic substances and infections [4, 11, 12]. Microorganisms

*Correspondence:

Mohsen Moghoofoei

mohsenmoghoofoei@yahoo.com; mohsen.moghoofoei@KUMS.a.ir

¹Department of Obstetrics and Gynecology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

²Infectious Diseases Research Center, Health Research Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

³Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

(viruses and bacteria) repeatedly invade the endometrial cavity/tissue. Implantation failure can be due to subclinical endometrial infection and/or chronic inflammation [13]. Although much research has evaluated and confirmed the involvement of bacterial infection agents in implantation failure [12], viral involvement is still questionable and needs more detailed studies. Viral infection of the trophoblast can impair its function, resulting in abnormal implantation. Possible causes of implantation failure include viruses that have little or no pathogenicity [14].

The current study set out to discuss the role of viral infection in implantation failure.

Inflammation and immune cells in implantation

There is a complex microenvironment in the placenta between the mother and the embryo that contains immune substances [15]. The mother's immune system has a crucial role in the embryo implantation, as the embryo is semi-allogeneic and different from the mother's cells [16]. Recent research has shown that implantation is a pro-inflammatory condition [17]. Besides, inflammation is proven to play a key role in maintaining and regenerating the uterus [18]. Pro-inflammatory cytokines produced by endometrial stromal cells that inflame the endometrium prior to the blastocyst invading [19, 20].

There are two types of the immune response, including T helper cell 1 (Th1) and Th2 [21, 22]. In Th1 response tends to produce the proinflammatory cytokines including interferon- γ (IFN γ), interleukins (IL1, IL2, IL6, IL12, IL15, and IL18), and TNF α . This response is involved in defense against intracellular parasites, and autoimmune responses [23, 24]. From the other point of view, in Th2 response IL4, IL5, IL-6, IL-9, IL10, IL13 (regulatory cytokines), and granulocyte macrophage colony stimulating factor (GM-CSF) are involved. This response is known as anti-inflammatory [25]. One of the immune system's primary responses is inflammation, which consists of molecular mediators, cytokines, chemokines, and immune cells [26]. Different factors are involved in provoking of the inflammatory process, including infection, viral and bacterial, and tissue injury [18].

This is an incredibly important point to remember, as a distinction must be made between acute and chronic inflammation, with acute inflammation being indispensable for implantation success, whereas chronic inflammation is destructive and causes RIF [27]. The inflammatory process causes local endometrial injury, which prolongs endometrial receptivity [18]. Furthermore, the positive effect of local endometrial injury on the success rate of IVF has been supported by a recent meta-analysis [28]. One study showed a decrease in the expression of programmed death 1 (PD-1) (an immune checkpoint) and

T cell immunoglobulin and mucin domain-3 (TIM-3) in the peripheral lymphocytes after the successful implantation of the blastocyst (on days 3 and 6). Since both of them are essential factors in anti-inflammatory process, this indicates that inflammation is involved in implantation [29]. On the contrary, at the end of menstruation, the decline in progesterone leads to the activation of the pro-inflammatory NF-kB pathway, and indeed causes the up-regulation of pro-inflammatory cytokines, matrix metalloproteinases and prostaglandins [18, 30]. Cytokines involved in the implantation process were described in details by Sieg et al. [27]. The essential function of antigen-presenting cells (APCs) in the cytokine profiles between maternal and fetal tissues has been confirmed by several studies [31, 32]. Another important factor is reactive oxygen and nitrogen species (RONS). Level of RONS may be involved in the implantation process so that overproduction of RONS can cause cell and tissue damage, as well as interfere with signaling pathways [33]. Nitric oxide (NO) plays a critical role in both endometrial tissue preparation for successful implantation and endometrial decidualization [34].

Immune cells have a critical function in inflammation, leading to tissue remodeling through the secretion of various cytokines and chemokines [18, 24, 31, 35]. Uterus infiltrated cells are uterine-specific natural killer (uNK) cells (65–70%), regulatory T Cells, Uterine Mast Cells (uMCs), macrophages, dendritic cells (DCs), and APCs (10–20%) [36–40]. These cells secrete cytokines and chemokines that are pro-inflammatory [24]. "Decidual natural killer (dNK) cells are differentiated from peripheral blood NK cells". These dNK cells have some characteristics, including poor cytolytic activity, secreting IFN-gamma-inducible protein 10 (IP-10; CXCL10), IL-8 and some other cytokines that are involved in trophoblast invasion and embryonic development [31, 41]. DCs, which act as initiators and coordinators of the innate adaptive immune response [42]. Prior to implantation, uterine DCs (uDCs) accumulate in the pregnant uterus. They remain in the decidua for the entire duration of pregnancy [32, 43]. One of the most important effects of uDC depletion is severe impairment of implantation [44]. Another important cell is the macrophage, which is involved in the decidualization and implantation [45, 46]. DCs and macrophages are involved in angiogenesis and remodeling of tissue by secreting chemokines, cytokines, and enzymes [46]. The first immune cells to be involved at the site of infection are neutrophils, which cause the amplification of inflammatory signals and attract immune cells. But the infiltration of neutrophils into the endometrial tissue is prevented, perhaps by suppressing the cytokine signaling involved in their recruitment [47, 48]. Although T cells are crucial in the implantation, they constitute a smaller proportion of the immune cells

of decidual compared to dNK and macrophages [16, 49, 50]. Th and T regulatory (Treg) cells have the key roles during implantation and pregnancy [16, 50]. All in all, immune cell infiltration is crucial in cell differentiation, tissue renewal and the development of a receptive endometrium.

In fact, there is a reciprocal relationship between sex steroids (progesterone, and estrogen) and inflammation. In addition, inflammation is related to successful implantation [18, 24, 51–53]. A challenging question is whether the maternal immune system is a friend or foe of pregnancy.

Impact of virus-induced heat shock proteins on embryo implantation

Heat shock proteins (HSPs), also known as chaperones are highly conserved protective protein substrates that are produced in all cells [54]. There are several processes involved. These include proper protein folding, protein trafficking, and assembly and/or disassembly of complex proteins [55]. Environmental stressors such as free oxygen radicals, hyperthermia, inflammation and infection lead to the expression of HSPs [56]. The role of HSPs in immunomodulation is that it causes the up-regulation of some factors such as some chemokines, interleukins (IL-1, IL-6, and IL-12), nitric oxide (NO), tumor necrosis factor (TNF- α), and even the maturation of DCs [55].

HSPs play a critical role in pregnancy, especially in the implantation process, where they are tasked with maintaining the proper microenvironment in the endometrial cells [56, 57]. HSPs can affect all stages of reproduction because they are the first proteins synthesized during embryonic development [58]. In mouse and rabbit models, HSPs have been shown to be produced during embryo preimplantation [59]. In addition, HSC70 is constitutively expressed during mouse embryo implantation [60].

Viral infection results in the cellular heat shock response and modulation of the expression of HSPs involved in implantation [61]. It has been demonstrated that some HSPs such as hsp60, hsc70, and hsp90 are up-regulated, while hsp28 is down-regulated [62, 63]. Previous researches have shown alteration of the HSPs during viral infection. Viruses such as Herpes simplex virus type 1 and 2 (HSV-1 and HSV-2), Varicella Zoster virus (VZV), Cytomegalovirus (CMV), Hepatitis C virus (HCV), Polioviruses (PV), and Epstein-Barr virus (EBV) [61, 64–68]. Viral infection of chick embryo cells has been shown to induce the expression of HSPs [69].

In general, it can be concluded that changes in the expression of HSPs by viruses can lead to disruption of the embryo implantation process.

Viral-induced immune responses

Viruses are necessary but not enough to cause disease, as are other pathogens, which are infection enigma [70]. Viral infection during pregnancy has several consequences, including premature birth, miscarriage and intrauterine growth restriction [71]. Viruses involved in implantation failure through two ways include: (i) direct way: infect endometrial and blastocyst cells, which leads to apoptosis, alteration of gene expression and decreasing trophoblast invasive activity; (ii) indirect way: disrupting the immune response (Fig. 1). The immune system has one primary strategy against viral infection. It is to eliminate the infected cells by type I IFNs (IFN- α and IFN- β), pro-inflammatory cytokines, and cytotoxic lymphocytes [72, 73]. The role of inflammatory cytokines in viral infection is mediated through several pathways including: (a) producing antiviral effector molecules directly, (b) indirect provocation of recruiting immune cells and the phagocytosis of infected cells, and (c) activation of acquired immune responses includes cytotoxic T lymphocytes (CTLs) and neutralizing antibodies [73–75]. Infected macrophages and DCs produce interleukins (IL-1 β , IL-6, IL-15, IL-18), and TNF as the major inflammatory cytokines [72, 73].

Human decidua contain a variety of immunocompetent cells including T cells, NK cells and macrophages [13]. Conversely, different cell types are involved in antiviral responses such as NK, DCs, monocyte, macrophages, and T cells [72, 76, 77]. NK cells have an important role in the elimination of virus-infected cells through the production of IFN- γ , which induces other antiviral mechanisms. Another cell is monocyte, which gives rise to DCs and macrophages when inside the tissue [72, 73]. Macrophages play a number of critical roles, including tissue homeostasis, wound healing and inflammation. Some macrophages prevent other cells from being infected by producing the highest levels of type I IFNs locally [73, 78, 79]. During viral infection, DCs have some functions such as antigen presentation, and cytokine production [72, 80]. Excessive leukocyte infiltration and activation of tissue-resident leukocytes are responsible for tissue inflammation during viral infection [81].

One of the critical factors for successful implantation is the local microenvironment at the cellular and molecular level at the fetal-maternal interface [13]. Many studies have shown that viral infection leads to changes in the cellular and molecular microenvironment of the target tissue. There are various imbalances such as inflammation, misplaced immune cell infiltration, production of RONS and alteration of normal cell signaling [82–86].




Fig. 1 Viruses lead to implantation failure by direct infection and disrupting the immune response

Virus infection and implantation failure

Viruses can infect the reproductive tract and affect the cells of these areas by modulating metabolism, biochemistry and the immune system. Therefore, there is an urgent need to assess the involvement of viruses in the embryo implantation and pregnancy outcomes. In support of this notion, some of the following evidence has been presented:

- i. Viruses can infect trophoblast cells,
- ii. Viruses have crucial roles in apoptosis of trophoblast cells, trophoblast gene expression alteration, decreases trophoblast invasive activity,
- iii. The viral genome was detected in placental tissue of implantation failure cases,
- iv. Detection of IgM antibodies against viruses [14] (Fig. 1).

In addition, implantation can be affected by viral infection by disrupting the normal function and secretory activity of endometrial cells in several ways, including:

- Immune modulation and cytokine production: As previously written, viral infections can modulate immune response and alter cytokine secretion by embryonic cells, resulting in an unfavorable microenvironment for implantation [5, 14, 87].

- Hormonal alterations: disruption of the hormonal balance occurs by some viral infections. Viruses cause damage to specific endocrine cells through replication in infected cells, cell lysis, and as a result of the immune response against viruses. Changing the production of progesterone and/or estrogen causes the implantation process to be impaired [88]. In SARS CoV-2 infection, alterations in hormonal levels have been seen, including increased level of luteinizing hormone (LH), prolactin, and follicle-stimulating hormone (FSH) [89]. HIV infection leads to increased activity of the pituitary gland, as evidenced by increased levels of TSH, prolactin, and ACTH [90]. Interestingly, some viruses encode some peptides called viral hormones with homology to human hormones (structural and/or functional) [91]. Inhibin β A chain, TGF- β 1, TGF- β 2, fibroblast growth factor, and IGF-2 are viral hormones that play a role in different stages of pregnancy [91].
- Apoptosis: some viruses cause implantation failure by inducing apoptosis in embryonic cells [92].
- Alteration of cell adhesion molecules: viruses can interfere with the normal expression of cell adhesion molecules on the surface of various cells such as immune cells and epithelial cells like those found in embryos [93–95].

Viral infection can change the gene expression patterns of endometrial and embryonic cells. For example, CMV causes disruption of the development of extracellular matrix (ECM), integrins and ultimately results in decreased cell adhesion and tissue invasion ability (implantation) [96–98]. Also, some viruses such as HHV-6 A interfere with trophoblast invasion by integrating their DNA into the host cell [99].

Overall, the success of implantation may be significantly influenced by the interaction between embryonic cell secretions and viral infections. However, specific details on the range of effects on secretions may require further study. There is lots of research that has been done on the influence of bacterial infection on embryo implantation [56, 100, 101], but the role of viral infection has not been reviewed much. We have set out to discuss the effects of some viruses on the implantation process as follows.

Human papillomavirus (HPV)

HPV is an oncogenic virus belonging to the Papillomaviridae family, which can infect the skin and mucous membranes [72]. HPV has multiple effects on reproductive function [102]. HPV infection in different tissues such as breast, prostate and lung results in increased expression of RONS, ILs (IL-1 α and β IL-6, IL-8), NF- κ B, MIP-1 α , and TNF- α [84, 85, 103, 104]. This viral infection is correlated with inflammation in mucous membranes, and skin [105]. HPV can cause chronic inflammation, change cell signaling, physiological cell death and cell transcriptome [85, 103, 106–108]. On the other hand, the negative immune-mediated effects of HPV on the implantation have been demonstrated in several studies [109]. Changes in cellular gene expression occur during persistent HPV infection, resulting in the expression of proinflammatory cytokine genes and abnormal immune cell infiltration [72, 84, 85, 103]. Another critical effect of HPV on cells (by E5 and E7 proteins (early proteins)) is to lead to down-regulation of some cell surface molecules such as human leukocyte antigen-G (HLA-G) and major histocompatibility complex class I (MHC I) that cause these cells to be lysed by NK cells, which are normally insensitive to NK cell lysis [110–112].

The trophoblast expresses the HLA-G as a requisite agent in the implantation process [112, 113]. In addition to the inverse effects of HPV on implantation, it causes activation of the immune response against the developing embryo by down-regulating the MHC I molecule [114]. HPV can lead to reduced implantation of trophoblastic cells through increased trophoblastic apoptosis, which was demonstrated by Zuo et al. [115, 116]. Also, Gomez et al. showed a greater rate of apoptosis (3- to 6-fold) in trophoblastic cells with HPV infection [117]. It has also been found that HPV can be transmitted during

fertilization and subsequently to the embryo [118–120]. The genome of HPV types 16 and 18 were detected in 108 patients with miscarriages [121]. The higher rate of HPV DNA detection in early miscarriage cases compared to voluntary terminations of pregnancy can demonstrate that HPV is involved in the pathophysiology of early pregnancy loss [122]. The effects of HPV on early development in the embryonic stage was demonstrated by Henneberg and colleagues. They showed the HPV type-specific effects on the blastocyst, as if HPV-16 led to a decrease in blastocyst formation, whereas HPV-18 was involved in inhibiting the blastocyst hatching process [123]. In another study, embryos exposed to HPV-16 were also shown a reduced implantation rate (less than 37.2%) by Hong et al. [121].

There is several research confirming the HPV effect on alterations in the immune response and cellular physiology that are involved in implantation. HPV as a frequent member of sexually transmitted infections (STI) may be an important hallmark in implantation failure. Most studies have reported the role of HPV types 16 and 18, but other HPV types may also be involved. Therefore, further studies are needed to clarify the involvement of all HPV types in implantation.

Herpes simplex virus (HSV) type 1 and 2

HSV types 1 and 2 (HSV-1 and HSV-2) are common members of the Herpesviridae family [72]. Both of them are in charge of cellular physiology alterations and necrosis, which leads to the inflammatory response [72, 124]. It has been shown that HSV-infected patients have concentrated inflammatory cytokines and high expression levels of apoptosis-related genes. This situation is also associated with HSV load [125]. Some pro-inflammatory cytokines such as IFN- α and - β , IL-6, IL-12, and TNF- α are involved in HSV immune mediated pathogenesis [126]. In a mouse model study, Felker and colleagues demonstrated that HSV-2 infection results in up-regulation of inflammatory cytokines and chemokines at the implantation site. They demonstrated the ability of HSV-2 to infect implantation sites such as the maternal decidua. Their results suggest that trophoblast cells can be infected by HSV-2 within implantation sites and induce abnormal trophoblast invasion [127]. The involvement of HSV in reproductive disease and pregnancy loss has been documented previously [128, 129]. Tsibizov et al. evaluated the impact of HSV-infected sperm on the fertilization efficiency and the frequency of embryo implantation. Their results indicated that the frequency of implantation was five times lower and the negative influence of HSV on the implantation [130]. In an interesting study, Yueh and colleagues have shown that up-regulation of VP16 (α -trans-inducing factor (α -TIF)) as a multifunctional protein of HSV is detrimental to preimplantation

development. They indicated that VP16 exerts its effects at the transition from the 2-cell to the 4-cell stage and leads to a reduction in blastocyst survival [72, 131].

Although the effect of HSV on implantation has been discussed, further researches is needed to determine its exact role in implantation failure.

Epstein - Barr virus (EBV)

Epstein-Barr virus (EBV) or Human herpesvirus type 4 (HHV4) is one of the most common viruses in humans (90% of the adult humans are seropositive) and belongs to the *Herpesviridae* family [72, 132]. EBV has been implicated in chronic inflammation in prostate, thyroid and breast tissue [83, 86, 133]. One study demonstrated that EBV infection was associated with the high levels of expression of inflammatory agents, which are involved in various pregnancy complications such as implantation failure [82]. There has been evidence that inflammation is increased in both latent and lytic EBV infection, and that inflammasome is triggered during EBV reactivation [134]. In research, Moghooei et al. demonstrated a positive correlation between EBV gene products (EBER, LMP-1, and LMP-2 A) and inflammatory agents including NF- κ B, IL-1, -6 and -10, IFN- α and - β , TNF- α , and ROS [86]. Implantation failure may be caused by this inflammatory state.

One of the most important effects of EBV on implantation is its influence on HLA-G, a cell surface molecule on placental tissue. HLA-G expression is up-regulated by IL-10, which has been demonstrated to be involved in the tumor cells' immune evasion [135, 136]. HLA-G, an antigen presenting protein, inhibits some immune cells such as NK cells, CD8 T and CD4 T cells, which is the most important factor in the immunosuppressive state responsible for immune tolerance during pregnancy [137]. The up-regulation of HLA-G is derived from the uterus environment, which is a fascinating concerted biological process and is involved in the immunological protection of the developing embryo [6]. Inflammation-related side effects may occur if immune tolerance mechanisms are disrupted. On the other hand, EBV can alter the expression of programmed cell deathligand 1 (PD-L1) [138]. This molecule is an immune checkpoint inhibitor and produced in placental trophoblasts and amniotic epithelial cells, which causes reduced lymphocyte proliferation through the secretion of immunosuppressive agents [139, 140]. Further research is needed to elucidate the involvement of EBV in the implantation failure.

Cytomegalovirus (CMV)

Human CMV or human herpesvirus type 5 (HHV-5) is another member of the *Herpesviridae* family with a seroprevalence of 60–90% worldwide [72, 141]. During CMV infection, there is a high number of differentiated

T cells (CD4+and CD8+) producing IL-1, IFN, TNF- α , granzyme B and perforin that may be involved in the implantation failure [142, 143]. Dons'koi et al. demonstrated that CMV infection gives rise to pro-inflammatory response in implantation failure cases. Also, they reported a dramatic up-regulation of HLA-DR on NK, T and NKT cells and a decrease in the number of CD8+NK lymphocytes in CMV-positive cases compared to negative ones. This research team claimed that the imbalance of CD8, CD69 and CD158 expression in NK subsets predicts implantation failure [144]. It has been shown that there is a significant association between anti-CMV IgG (previous exposure) and Recurrent Pregnancy Loss (RPL) [145]. Several research have reported the high rate of anti-CMV IgG in recurrent miscarriage cases, including Augustine et al. (85.7%), Sherkat et al. (90.6%), Kafi et al. (97.8%), and Hamed et al. (92.9%) [145–147].

Fisher et al. could not detect the CMV genome but they indicated that this virus has a role in implantation failure through diminishing normal functions of the placental trophoblasts [148]. CMV gene expression is affected by acidic environment and estrogen in such a way that CMV replication is inhibited by acidic environment and only the immediate early (IE) and early (E) genes are expressed [149–151]. There are fundamental effects exerted by CMV gene expression patterns on host cells and the immune system. Some proteins are translated by the IE and E genes, which are involved in causing chronic inflammation [152]. As most of the data on the involvement of CMV in embryo implantation and female reproduction is somewhat inconclusive, further studies with more detail are needed to clarify new aspects.

Human herpesvirus 6, 7 and 8

Human herpesvirus 6 (HHV-6), HHV-7 and HHV-8 (KSHV) are other members of the *Herpesviridae* family [72]. HHV-6 is divided into two variants, including HHV-6 A and HHV-6B, which primarily infects T cells [153]. However, it has broad tropism for a variety of cells [154]. Some researchers have indicated shedding of HHV-6 from the genital tract (25%) [155–157]. HHV-6 and HHV-7 have critical roles in implantation failure by altering the uterine microenvironment and by disrupting endothelial cell function [154, 158, 159]. One study investigated the prevalence of HHV-6 in the endometrial tissue of RIF cases (37% compared to 0% in controls). There was also no any difference in expressing the following NK cell-related markers such as CD16a, CD56, and CD57 and T cell markers such as CD3e in HHV-6 positive cases than normal controls [160]. Marci et al. found HHV-6 A genome in 43% of endometrial biopsies from women with primary unexplained infertility and 0% in controls. Interestingly, genome of HHV-6B was not detected in endometrial biopsies while it was detected in PBMCs of both

groups (25% and 28% of infertility and control women, respectively). Since the role of NK cells in implantation is one of the most controversial issues, this research group demonstrated that endometrial HHV-6 A-specific NK cells were induced. Besides, they showed an up-regulation and down-regulation of IL-10 and IFN- γ in infertile women with HHV6-A infection, respectively [154]. The high load of HHV6-A genome was reported in a previous study as 670.000–250.000 copies/ug [154].

According to previous studies, the endometrial tissue of infertile women is a suitable site for HHV-6 A infection, and unidentified microenvironmental factors are the determinants of HHV-6 A replication/infection. For example, high levels of estradiol may act as a positive cofactor in the induction of HHV-6 infection in the endometrium [154, 161]. HHV-6 A may contribute to altering the immune phenotype of eNK cells and cytokine levels such that Th2 IL-10 cytokine increases while Th1 IFN- γ cytokine decreases, which correlates with condition of female infertility [154, 162]. Moreover, HHV-6 infection up-regulates IL-10 by monocytes while decreasing the production of IFN- γ by T cells [163, 164]. Also, a positive correlation between HHV-6 antibody levels and implantation failure was found in two studies by Ando et al. and Drago et al. [165, 166].

Infection of cells by HHV-7 make cellular changes and alterations in the gene expression, though the full impact on cell function is still being researched and there is no research on the role of this virus in implantation failure. More studies are needed to clarify the role of HHV-7 in infertility and implantation problems, as well as to determine if screening for and treating HHV-7 infections could improve outcomes for women undergoing fertility treatments.

HHV-8 can induce a change in the cellular physiology and disrupt the immune system. B-lymphocyte is the main target cells of HHV-8. This virus causes chronic inflammation (cytokine and ROS production) by producing vIL-6 (viral interleukin 6) [167]. This situation leads to implantation failure. Trophoblast and endothelial cells are permissive host cells for HHV-8, which negatively affects them by increasing apoptosis rates [168].

The ability of the Herpesviridae family to modulate immune responses is the most critical point about the ability of these viruses to cause fertility disorders such as implantation failure.

Hepatitis B virus (HBV)

HBV is a double-stranded DNA virus (partially) belongs to the Hepadnaviridae family, which causes hepatitis B [72, 132]. Although HBV can cause potentially serious conditions in endometrial tissue, its presence is rare and occurs in women with chronic HBV infection [169]. Immune system responses resulting in changes

in the female genital tract microbiome, which are implicated in implantation failure are some consequences of chronic HBV infection [170]. HBV triggers the inflammatory response through the NF- κ B pathway via TLR2 and MyD88 leading to the production of IL-1, -2, -4, -6, -12, -17, IFNs, and TNF- α [171, 172]. Mucin 1 (MUC1) and osteopontin (SPP1) are crucial in endometrial receptivity [173]. Złotkowska and colleagues evaluated the expression of several chemokines including CCL2, CCL4, CCL5, CCL8, CXCL2, CXCL8, CXCL10, and CXCL12 in endometrial epithelial cells. They demonstrated that the provision of a suitable microenvironment for successful implantation is mediated by CCL8, while CXCL12 plays a critical role in enhancing endometrial receptivity and promoting embryo attachment [173]. Previous research indicated that the up-regulation of some chemokines, such as CXCL9-11, 10, 11, and 13 in endometrial tissue from HBV-positive patients compared to healthy individuals [171]. HBV proteins such as HBx promote up-regulation and/or down-regulation of some of the chemokines listed above [174].

All these alterations can result in implantation failure by modulating endometrium gene expressions. Li et al. showed some changes including reduced toxicity and cell functional activities of NK cells and a decrease in the number of CD3+CD4+helper T cells in HBV infected women, which contribute to adverse pregnancy outcomes such as implantation failure [175]. By inducing widespread chronic inflammation, HBV infection also causes implantation failure [176, 177]. In a study, 190 women who were undergoing their first IVF and embryo transfer cycles, the implantation rate (as one of the most important factors) was dramatically higher in HBV-positive women in comparison to controlled ones [178].

Further studies are needed regarding HBV infection due to the severe effects this virus causes.

SARSCoV-2

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) belongs to the Coronaviridae family with a positive single-stranded RNA [179]. The main consequence of SARS-CoV-2 infection is cytokine storm or hypercytokinemia, in which pro-inflammatory cytokines are released in an uncontrolled and excessive manner [180, 181]. An important effect of this virus is the up-regulation of angiotensin converting enzyme 2 (ACE2) and serine 2 (TMPRSS2), which ACE2 is highly expressed in many tissues and serves as a receptor for SARS-CoV-2 [182, 183]. Endometrial tissue is affected by SARS-CoV-2 through TMPRSS4 and, it is confirmed by microarray data [182, 184].

In an interesting study, a single-cell RNA-sequencing dataset and two microarray datasets were applied to determine SARS-CoV-2-related gene expression profiles.

Qi and colleagues demonstrated the up-regulation of Basigin (BSG) in the endometrial tissue of women with RPL. Their results indicated the endometrial tissue is highly susceptible to SARS-CoV-2 infection, leading to implantation failure [185]. In contrast, a meta-analysis study reported that no significant differences were found in implantation rates between the infected group and controls (OR 0.99, 95% CI 0.67–1.46; $P=0.96$). The results of this study suggest that, infection with COVID-19 does not affect the rate of implantation in IVF treatment [186]. In addition, during COVID-19 VEGF is up-regulated, but cannot result in the attachment of embryo and implantation failure [187, 188]. A research group evaluated whether COVID-19 infection is related to implantation failure. The results demonstrated that no significant differences were found in the implantation rates in three groups, including infected patients before and after frozen embryo transfer (FET) (29.14% and 30.38%), and patients without infection (31.03%) [189].

In the case of SARS-CoV-2 further research is crucial to investigate the role of the Coronavirus in implantation.

Zika virus (ZIKV)

ZIKV is a member of the Flaviviridae family, which are enveloped viruses with positive-strand RNA [190]. This virus impairs neuronal development and its pathogenesis is by suppressing the Akt-mTOR pathway and leading to cellular dysregulation [191].

Previous studies have demonstrated that ZIKV can affect the blastocyst and endometrial tissue to cause secretion of IL-6, VEGF-A, and Chemoattractant Protein-1 (MCP1) by the embryo, confirming a possible role of ZIKV in the blastocyst implantation [192]. VEGF-A, and MCP1 are crucial for implantation [193, 194]. Some members of the Flaviviridae family cause some changes during pregnancy, such as inflammation in the placenta, and up-regulation of VEGF and MCP1 [195]. Tan et al. demonstrated the effect of ZIKV on implantation failure and miscarriage. Also, 50–70% reduction in pregnancy rates was reported in a mouse model following subcutaneous ZIKV inoculation. They showed that ZIKV infection targets trophoblast cells and leads to apoptosis [196]. Another study has shown that ZIKV replication can occur in the trophoblast and during implantation, altering trophoblast function [197].

Although there are few previous investigations on ZIKV involvement in implantation, further in vivo research is necessary for the determination of the role of ZIKV in embryo implantation.

Microbial-host interaction is the strongest shaping force in how the immune system evolves and develops. Infections of the genital tract and the pathological inflammation associated with them are vital to the successful process of reproduction.

MicroRNAs

However, several previous reviews have discussed the role of microRNAs (miR or miRNAs) in embryo implantation. In this study, we will discuss some miRNAs that have deregulated expression levels are involved in implantation failure and are also affected by viral infections. One of the main ways that viruses can affect the implantation failure is that viruses lead to altering the expression miRNAs in endometrial tissue. MiRNAs are a class of non-coding regulatory RNAs, which have about 19–25 nucleotides (nt) in length [198, 199]. Totally, more than 300 human miRNAs have been identified that affect various biological functions by the regulation of the expression of about 60% of human protein-coding genes [198, 200–202]. Because viruses as intracellular parasites can modify how targeted cells behave. Viruses can alter the expression of cellular miRNA and, in fact, they disrupt cellular processes [203, 204]. Viruses can be affected by miRNAs in two ways as follow; direct way as targeting viral mRNAs in the 3'UTR (untranslated region) and indirectly, by modulating the expression of host factors that are essential for the replication of the virus [204, 205].

The differential expression of miRNAs have been demonstrated in different stages and/or pathological conditions of endometrial tissue [206, 207]. Furthermore, the different miRNAs profiling has been seen in endometrium from failed and recurrent failed implantation [208]. There are two main types of miRNAs in implantation, including pro-implantation miRNAs and anti-implantation miRNAs. Pro-implantation miRNAs are up-regulated prior to implantation, while anti-implantation miRNAs are up-regulated in the event of implantation failure [209]. The differential expression of 13 miRNAs (10 miRNAs were up-regulated and 3 were down-regulated) in RIF patients was first reported by Revel et al. in 2011 [210].

The first one was miR-145, which is expressed in a number of tissues such as the prostate, the ovary, the heart and the uterus [211]. MiR-145 has also contributed to the regulation of decidua cell proliferation and in the differentiation of endometrial tissue [211, 212]. Several targets were introduced for this miR such as octamer-binding transcription factor 4 (OCT4), mucin 1 (Muc1), homeobox A10 and A11 (HOXA10, HOXA11), estrogen receptor alpha (Era), and insulin-like growth factor 1 receptor (IGF1R) [207]. A previous study has shown an up-regulation of miR-145 in patients with RIF compared to controls (a 3-fold increase) [213]. Up-regulation of miR-145 has been shown to be involved in the inhibition of mouse embryo attachment to the endometrium [214]. Another critical effect of miR-145 in the genital tract is on implantation by down-regulating of Phenylalanine ammonia-lyase 1 (PAL-1) [210, 213]. Furthermore, this

miR leads to infertility through inhibiting the expression of HOXA10 and HOXA11 [215]. HPV causes a significant decrease in miR-145 expression in penile cancer [216]. Yu et al. showed the significant down-regulation of miR-145 in HPV-positive cervical cancer cases compared to HPV-negative ones [217]. There is a reciprocal relationship between miR-145 expression and HPV replication, so that HPV causes significant down-regulation of miR-145 and up-regulation of it can inhibit HPV replication [216, 218]. MiR-145 inhibits the expression of certain HPV mRNAs such as E1 and E2 (early protein), which are involved in viral replication [219]. A significant association has been indicated between EBV infection and lower levels of miR-145 expression in some tumor tissues compared to normal ones [220]. Okoye and colleagues have shown that an up-regulation of miR-145 status in HSV-2 infection of cervical lesions compared to HSV-2 negative tissue. They also showed that miR-145 was up-regulated in cases of viral mono-infection and down-regulated in cases of viral co-infection compared to participants without viral infections [221]. It has also been shown that CMV inhibits miR-145 expression. This leads to the up-regulation of Sox2 and subsequently to the proliferation of some cells [222].

Mir-22 was first identified in HeLa cells. Then was identified in a some tissues [223]. This miR is involved in various biological pathways such as apoptosis, cell proliferation and cell migration and it is a tumor suppressor [224, 225]. On the basis of the role played by immune cells and their secretions in the process of implantation, recent research demonstrated that the expression level of PD-L1 is decreased by miR-22, which causes T cell-mediated immune responses [226]. Moreover, this miR leads to activate myeloid DCs to indirectly regulate the T helper 17 (Th17) in the mouse model [227]. Interestingly, miR-22 is considered as an anti-implantation miRNA that is up-regulated during normal implantation in RIF patients. This miR through targeting T-Lymphoma Invasion and Metastasis-Inducing Protein 1 (Tiam1) results in the dysregulation of decidualization in endometrial stromal cells. Tiam1 and Race1 are involved in implantation [228]. One study showed that up-regulation of miR-22 caused down-regulation of Tiam1, resulting in embryo implantation in mice. It has also been shown that estrogen (E2) and progesterone (P) interact to regulate miR-22, Tiam1, and Rac1 [229]. In addition, the dysregulated expression of miR-22, Race1 and Tiam1 are associated with a decreased progesterone to estradiol (P/E2) ratio in RIF patients [207]. HPV E6 protein (early protein) leads to down-regulation of miR-22 through suppression of p53 in cervical cancer cell lines [224]. In contrast, a significant correlation between HPV-16 infection and up-regulation of miR-22-3p was demonstrated by Kwon et al. [230]. Several studies showed a significant correlation

between HBV infection and down-regulation of miR-22 [231, 232]. The effect of HHV-6 A on miR-22 is in such a way that this virus significantly increases the expression of miR-22 in the cells of the endometrium [99].

MiR-181 plays an important role in the cellular processes such as angiogenesis, apoptosis, autophagy, and the pro-differentiation of some cell lineages including immune cells (NK/NKT cells, B cells, and T cells), megakaryocytes and myoblasts [233, 234]. In patients with RIF, miR-181 is down-regulated [235]. Some sex hormones such as estrogen cause down-regulation of miR-181 by regulating the expression level of empty spiracles homeobox 2 (EMX2) [207, 236]. Down-regulation of miR-181 results in up-regulation of Leukemia inhibitory factor (LIF) and subsequent implantation success. LIF belongs to the IL-6 family, which leads to the uterus for embryos to be implanted [207, 237]. Another important effect of miR-181 is the downregulation of KLF transcription factor 12 (KLF12), which is involved in endometrial receptivity. The expression level of KLF12 is found to be high in endometriosis and RIF patients [238]. Some viral infections such as HPV and SARS-CoV-2 cause down-regulation of miR-181 while other viruses like EBV, HBV, and HHV-6 A lead to up-regulation [239–241].

The expression of miR-661 was evaluated in a study that showed significant up-regulation of this miR in blastocysts from women with failed implantation [242]. MiR-661 causes down-regulation of Mdm2 and Mdm4 that leads to p53 activation [243]. On the other hand, in addition to causing the proteolytic degradation of p53, HPV causes down-regulation of miR-661 to prevent the activity of p53 [85, 244, 245]. Also, HBV leads to down-regulation of miR-661 [246].

One of the HBV proteins (HBx) down-regulates miR-661 that suppresses Metastasis-associated protein 1 (MTA1) with some important cellular functions in endometrial tissue [247, 248].

Previous data suggests that miR-30 is involved in both the physiological (tissue development) and pathogenic disease processes [249]. This miR is up-regulated in the endometrium and has a negative correlation with forkhead box P3 (FOXP3), which regulates CXCL12 expression [250]. On the other side, the immune-tolerant environment in the endometrium is associated with uNK cells attracted by CXCL12 [208]. One study profiled miRNA expression in uterine aspirates collected overnight before frozen embryo transfer. Park and colleagues reported that three miR, miR-891a, miR-198, and miR-522, were down-regulated in the implantation failure cases [251].

All in all, virus alters some cellular and molecular processes in the endometrial cells. Viruses by deregulation of cellular miRNAs lead to disruption of the cell

microenvironment and many cellular functions such as the implantation process.

Conclusion

In this review, we reviewed studies analyzing the role of viral infections and miRNAs expression changes in the endometrium, which are crucial in the likelihood of successful implantation. Although several studies have been conducted on factors involved in embryo implantation, based on our search the role of viruses and the role of interaction of viruses and cellular miRNAs has not been investigated in previous studies. All these results suggest that viruses play a crucial role in the implantation failure process as a confounding factor. However, further studies are needed to confirm the role of viral infection and viral-induced miRNAs in implantation failure.

Acknowledgements

We tender our apologies to those authors whose deserving research was not cited in this manuscript.

Author contributions

MR and MM provided outlines for the manuscript. MR and MM drafted the manuscript. MM provided critical revision to the abstract and manuscript. MR and MM approved the final version.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability

All included articles during the current study could be made available through the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

This study did not require ethical approval or patient consent. All analyses were performed according to previously published studies.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 10 August 2024 / Accepted: 22 October 2024

Published online: 11 November 2024

References

1. Carson DD, Bagchi I, Dey SK, Enders AC, Fazleabas AT, Lessey BA, Yoshinaga K. Embryo implantation. *Dev Biol*. 2000;223:217–37.
2. Muter J, Lynch VJ, McCoy RC, Brosens JJ. Human embryo implantation. *Development*. 2023;150:dev201507.
3. Sharkey AM, Smith SK. The endometrium as a cause of implantation failure. *Best Pract Res Clin Obstet Gynecol*. 2003;17:289–307.
4. Cakmak H, Taylor HS. Implantation failure: molecular mechanisms and clinical treatment. *Hum Reprod Update*. 2011;17:242–53.
5. Johnson P, Christmas S, Vince G. Immunological aspects of implantation and implantation failure. *Hum Reprod*. 1999;14:26–36.
6. Moreau P, Adrian-Cabestre F, Menier C, Guiard V, Gourand L, Dausset J, Carosella ED, Paul P. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. *Int Immunol*. 1999;11:803–11.
7. Mathew DJ, Lucy MC, Geisert RD. Interleukins, interferons, and establishment of pregnancy in pigs. *Reproduction*. 2016;151:R111–122.
8. Yang Y, Zhu QY, Liu JL. Deciphering mouse uterine receptivity for embryo implantation at single-cell resolution. *Cell Prolif*. 2021;54:e13128.
9. Ma J, Gao W, Li D. Recurrent implantation failure: a comprehensive summary from etiology to treatment. *Front Endocrinol*. 2023;13:1061766.
10. Timeva T, Shterev A, Kyurkchiev S. Recurrent implantation failure: the role of the endometrium. *J Reprod Infertility*. 2014;15:173.
11. Donaghy M, Lessey BA. Uterine receptivity: alterations associated with benign gynecological disease. *Seminars in reproductive medicine*. © Thieme Medical; 2007. pp. 461–75.
12. Matovina M, Husnjak K, Milutin N, Ciglar S, Grce M. Possible role of bacterial and viral infections in miscarriages. *Fertil Steril*. 2004;81:662–9.
13. Romero R, Espinoza J, Mazor M. Can endometrial infection/inflammation explain implantation failure, spontaneous abortion, and preterm birth after in vitro fertilization? *Fertil Steril*. 2004;82:799–804.
14. Arechavaleta-Velasco F, Koi H, Strauss JF III, Parry S. Viral infection of the trophoblast: time to take a serious look at its role in abnormal implantation and placentation? *J Reprod Immunol*. 2002;55:113–21.
15. Bonney EA. Immune regulation in pregnancy: a matter of perspective? *Obstet Gynecol Clin*. 2016;43:679–98.
16. Zhang Y, Liu Z, Sun H. Fetal-maternal interactions during pregnancy: a 'three-in-one' perspective. *Front Immunol*. 2023;14:1198430.
17. Sehring J, Beltsos A, Jeelani R. Human implantation: the complex interplay between endometrial receptivity, inflammation, and the microbiome. *Placenta*. 2022;117:179–86.
18. Granot I, Gnainsky Y, Dekel N. Endometrial inflammation and effect on implantation improvement and pregnancy outcome. *Reproduction*. 2012;144:661–8.
19. Hinduja I, Pathare AD, Zaveri K, Hinduja I. Immunological approach of personalized treatment for recurrent implantation failure patients undergoing IVF. *Global J Reproductive Med*. 2018;5:65–7.
20. Salama KM, Alloush MK. Are the cytokines TNF alpha and IL 1Beta early predictors of embryo implantation? Cross sectional study. *J Reprod Immunol*. 2020;137:102618.
21. Kalagiri RR, Carder T, Choudhury S, Vora N, Ballard AR, Govande V, Drever N, Beeram MR, Uddin MN. Inflammation in complicated pregnancy and its outcome. *Am J Perinatol*. 2016;33:1337–56.
22. Nathan C. Points of control in inflammation. *Nature*. 2002;420:846–52.
23. Mor G, Cardenas I, Abrahams V, Guller S. Inflammation and pregnancy: the role of the immune system at the implantation site. *Ann NY Acad Sci*. 2011;1221:80–7.
24. Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss JF III, Petraglia F. Inflammation and pregnancy. *Reproductive Sci*. 2009;16:206–15.
25. Berger A. Th1 and Th2 responses: what are they? *BMJ*. 2000;321:424.
26. Nathan C, Ding A. Nonresolving inflammation. *Cell*. 2010;140:871–82.
27. Sieg W, Kiewisz J, Podolak A, Jakiel G, Woclawek-Potocka I, Lukaszuk J, Lukaszuk K. Inflammation-related molecules at the maternal–fetal interface during pregnancy and in pathologically altered endometrium. *Curr Issues Mol Biol*. 2022;44:3792–808.
28. El-Toukhy T, Sunkara S, Khalaf Y. Local endometrial injury and IVF outcome: a systematic review and meta-analysis. *Reprod Biomed Online*. 2012;25:345–54.
29. Zhang T, Zhu W, Zhao Y, Cheung WC, Liu Y, Chen X, Du Y, Leung KT, Chan YL, Wang CC. Early transient suppression of immune checkpoint proteins T-cell immunoglobulin mucin-3 and programmed cell death-1 in peripheral blood lymphocytes after blastocyst transfer is associated with successful implantation. *Fertil Steril*. 2020;114:426–35.
30. Kelly RW, King AE, Critchley H. Cytokine control in human endometrium. *Reproduction*. 2001;121:3–19.
31. Mor G. Inflammation and pregnancy: the role of toll-like receptors in trophoblast–immune interaction. *Ann NY Acad Sci*. 2008;1127:121–8.
32. Laskarin G, Kämmerer U, Rukavina D, Thomson AW, Fernandez N, Blois SM. Antigen-presenting cells and materno-fetal tolerance: an emerging role for dendritic cells. *Am J Reprod Immunol*. 2007;58:255–67.
33. Hameister R, Kaur C, Dheen ST, Lohmann CH, Singh G. Reactive oxygen/nitrogen species (ROS/RNS) and oxidative stress in arthroplasty. *J Biomedical Mater Res Part B: Appl Biomaterials*. 2020;108:2073–87.
34. Tseng L, Zhang J, Peresleni TY, Goligorsky MS. Cyclic expression of endothelial nitric oxide synthase mRNA in the epithelial glands of human endometrium. *J Soc Gynecol Investig*. 1996;3:33–8.

35. Yoshinaga K. Review of factors essential for blastocyst implantation for their modulating effects on the maternal immune system. In *Seminars in cell & developmental biology*. Elsevier; 2008: 161–169.
36. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. *Nat Med*. 2006;12:1065–74.
37. Kämmerer U, Rieger L, Honig A, Kämpgen E. Characterization of human dendritic cells at the materno-fetal interface. In *Immunology of Pregnancy*. Springer; 2006: 122–129.
38. Abrahams VM, Kim YM, Straszewski SL, Romero R, Mor G. Macrophages and apoptotic cell clearance during pregnancy. *Am J Reprod Immunol*. 2004;51:275–82.
39. Le Bouteiller P, Piccinni MP. Human NK cells in pregnant uterus: why there? *Am J Reprod Immunol*. 2008;59:401–6.
40. Meyer N, Zenclussen AC. Immune cells in the uterine remodeling: are they the target of endocrine disrupting chemicals? *Front Immunol*. 2020;11:246.
41. Zhang X, Wei H. Role of decidual natural killer cells in human pregnancy and related pregnancy complications. *Front Immunol*. 2021;12:728291.
42. Granucci F, Foti M, Ricciardi-Castagnoli P. Dendritic cell biology. *Adv Immunol*. 2005;88:193–233.
43. Kämmerer U. Antigen-presenting cells in the decidua. *Immunol Pregnancy*. 2005;89:96–104.
44. Plaks V, Birnberg T, Berkutzi T, Sela S, BenYashar A, Kalchenko V, Mor G, Keshet E, Dekel N, Neeman M. Uterine DCs are crucial for decidua formation during embryo implantation in mice. *J Clin Investig*. 2008;118:3954–65.
45. Aplin AC, Nicosia RF. Regulation of angiogenesis by macrophages, dendritic cells, and circulating myelomonocytic cells. *Curr Pharm Design*. 2009;15:365–79.
46. Chishima F, Nakajima T, Nakao T, Hayashi C, Ichikawa G, Komatsu A, Kawana K. The inflammatory process and successful implantation. *J Mammalian Ova Res*. 2017;34:75–81.
47. Fülöp V, Vermes G, Demeter J. The relationship between inflammatory and immunological processes during pregnancy. Practical aspects. *Orv Hetil*. 2019;160:1247–59.
48. Chavan AR, Griffith OW, Wagner GP. The inflammation paradox in the evolution of mammalian pregnancy: turning a foe into a friend. *Curr Opin Genet Dev*. 2017;47:24–32.
49. Robertson SA, Care AS, Moldenhauer LM. Regulatory T cells in embryo implantation and the immune response to pregnancy. *J Clin Investig*. 2018;128:4224–35.
50. Tilburgs T, Roelen DL, van der Mast BJ, de Groot-Swings GM, Kleijburg C, Scherjon SA, Claas FH. Evidence for a selective migration of fetus-specific CD4+CD25bright regulatory T cells from the peripheral blood to the decidua in human pregnancy. *J Immunol*. 2008;180:5737–45.
51. Dominguez F, Galan A, Martin JLL, Remohi J, Pellicer A, Simón C. Hormonal and embryonic regulation of chemokine receptors CXCR1, CXCR4, CCR5 and CCR2B in the human endometrium and the human blastocyst. *Mol Hum Reprod*. 2003;9:189–98.
52. Kitaya K, Nakayama T, Okubo T, Kuroboshi H, Fushiki S, Honjo H. Expression of macrophage inflammatory protein-1 β in human endometrium: its role in endometrial recruitment of natural killer cells. *J Clin Endocrinol Metabolism*. 2003;88:1809–14.
53. Carlino C, Stabile H, Morrone S, Bulla R, Soriani A, Agostinis C, Bossi F, Mocchi C, Sarazani F, Tedesco F. Recruitment of circulating NK cells through decidual tissues: a possible mechanism controlling NK cell accumulation in the uterus during early pregnancy. *Blood J Am Soc Hematol*. 2008;111:3108–15.
54. Tutar L, Tutar Y. Heat shock proteins; an overview. *Curr Pharm Biotechnol*. 2010;11:216–22.
55. Zininga T, Ramatsui L, Shonhai A. Heat shock proteins as immunomodulators. *Molecules*. 2018;23:2846.
56. Neuer A, Spandorfer S, Giraldo P, Dieterle S, Rosenwaks Z, Witkin S. The role of heat shock proteins in reproduction. *Hum Reprod Update*. 2000;6:149–59.
57. Tabibzadeh S, Broome J. Heat shock proteins in human endometrium throughout the menstrual cycle. *Infect Dis Obstet Gynecol*. 1999;7:5–9.
58. Jee B, Dhar R, Singh S, Karmakar S. Heat shock proteins and their role in pregnancy: redefining the function of Old Rum in a New Bottle. *Front Cell Dev Biology*. 2021;9:648463.
59. Walsh DA, Edwards MJM, Smith MS. Heat shock proteins and their role in early mammalian development. *Exp Mol Med*. 1997;29:139–50.
60. Mezger V, Legagneux V, Babinet C, Morange M, Bensaude O. Heat shock protein synthesis in preimplantation mouse embryos and embryonal carcinoma cells. *Heat Shock Dev* 1991:153–66.
61. Santoro MG, Amici C, Rossi A. Role of heat shock proteins in viral infection. *Prokaryotic Eukaryotic Heat Shock Proteins Infect Disease* 2010:51–84.
62. Honoré B, Rasmussen HH, Celis A, Leffers H, Madsen P, Celis JE. The molecular chaperones HSP28, GRP78, endoplasmic reticulum chaperone exhibit strikingly different levels in quiescent keratinocytes as compared to their proliferating normal and transformed counterparts: cDNA cloning and expression of calnexin. *Electrophoresis*. 1994;15:482–90.
63. Sainis I, Angelidis C, Pagoulatos G, Lazaridis I. The hsc70 gene which is slightly induced by heat is the main virus inducible member of the hsp70 gene family. *FEBS Lett*. 1994;355:282–6.
64. Cheung RK, Dosch H-M. The growth transformation of human B cells involves superinduction of hsp70 and hsp90. *Virology*. 1993;193:700–8.
65. Santomena LD, Colberg-Poley AM. Induction of cellular hsp70 expression by human cytomegalovirus. *J Virol*. 1990;64:2033–40.
66. Ohgitani E, Kobayashi K, Takeshita K, Imanishi J. Induced expression and localization to nuclear-inclusion bodies of hsp70 in varicella-zoster virus-infected human diploid fibroblasts. *Microbiol Immunol*. 1998;42:755–60.
67. Notarianni EL, Preston CM. Activation of cellular stress protein genes by herpes simplex virus temperature-sensitive mutants which overproduce immediate early polypeptides. *Virology*. 1982;123:113–22.
68. Liberman E, Fong Y-L, Selby MJ, Choo Q-L, Cousens L, Houghton M, Benedict Yen T. Activation of the grp78 and grp94 promoters by hepatitis C virus E2 envelope protein. *J Virol*. 1999;73:3718–22.
69. Garry RF, Ulug ET, Bose HR Jr. Induction of stress proteins in Sindbis virus- and vesicular stomatitis virus-infected cells. *Virology*. 1983;129:319–32.
70. Dubos RJ. Second thoughts on the germ theory. *Sci Am*. 1955;192:31–5.
71. Chudnovets A, Liu J, Narasimhan H, Liu Y, Burd I. Role of inflammation in virus pathogenesis during pregnancy. *J Virol*. 2020;95. <https://doi.org/10.1128/jvi.01381-20>.
72. Fields BN. *Fields' virology*. Lippincott Williams & Wilkins; 2007.
73. Takeuchi O, Akira S. Innate immunity to virus infection. *Immunol Rev*. 2009;227:75–86.
74. Braciale TJ, Hahn YS. Immunity to viruses. *Immunol Rev*. 2013;255:5.
75. Zhang SY, Jouanguy E, Sancho-Shimizu V, Von Bernuth H, Yang K, Abel L, Picard C, Puel A, Casanova JL. Human toll-like receptor-dependent induction of interferons in protective immunity to viruses. *Immunol Rev*. 2007;220:225–36.
76. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+T cells in immunity to viruses. *Nat Rev Immunol*. 2012;12:136–48.
77. Bloom BR, Rager-Zisman B. Cell-mediated immunity in viral infections. *Viral immunology and immunopathology*. Elsevier; 1975. pp. 113–36.
78. Nikitina E, Larionova I, Choizonov E, Kzhyskowska J. Monocytes and macrophages as viral targets and reservoirs. *Int J Mol Sci*. 2018;19:2821.
79. Knoll R, Schultze JL, Schulte-Schrepping J. Monocytes and macrophages in COVID-19. *Front Immunol*. 2021;12:720109.
80. Marongiu L, Valache M, Facchini FA, Granucci F. How dendritic cells sense and respond to viral infections. *Clin Sci*. 2021;135:2217–42.
81. Casanova J-L, Abel L. Mechanisms of viral inflammation and disease in humans. *Science*. 2021;374:1080–6.
82. Papadatou V, Tologkos S, Deftereou T, Alexiadi T, Pagonopoulou O, Alexiadi C-A, Bakatselou P, Oglou STC, Tripsianis G, Mitrakas A. Viral-induced inflammation can lead to adverse pregnancy outcomes. *Folia Medica*. 2023;65:744–52.
83. Nahand JS, Khanaliha K, Mirzaei H, Moghooei M, Baghi HB, Esghaei M, Khatami AR, Fatemipour M, Bokharaei-Salim F. Possible role of HPV/EBV coinfection in anoikis resistance and development in prostate cancer. *BMC Cancer*. 2021;21:1–19.
84. Fatemipour M, Nahand JS, Azar MEF, Baghi HB, Taghizadeh M, Sorayayyi S, Hussen BM, Mirzaei H, Moghooei M, Bokharaei-Salim F. Human papillomavirus and prostate cancer: the role of viral expressed proteins in the inhibition of anoikis and induction of metastasis. *Microb Pathog*. 2021;152:104576.
85. Khodabandehlou N, Mostafaei S, Etemadi A, Ghasemi A, Payandeh M, Hadifar S, Norooznejad AH, Kazemnejad A, Moghooei M. Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins. *BMC Cancer*. 2019;19:1–11.
86. Moghooei M, Mostafaei S, Nesaei A, Etemadi A, Sadri Nahand J, Mirzaei H, Rashidi B, Babaei F, Khodabandehlou N. Epstein-Barr virus and thyroid cancer: the role of viral expressed proteins. *J Cell Physiol*. 2019;234:3790–9.
87. Ostanin A, Aizikovitch B, Aizikovitch I, Kozhin AY, Chernykh E. Role of cytokines in the regulation of reproductive function. *Bull Exp Biol Med*. 2007;143:75–9.

88. Nekoua MP, Debuyschere C, Vergez I, Morvan C, Mbani CJ, Sane F, Alidjinou EK, Hober D. Viruses and endocrine diseases. *Microorganisms*. 2023;11:361.
89. Wei L, Sun S, Zhang J, Zhu H, Xu Y, Ma Q, McNutt MA, Korteweg C, Gu J. Endocrine cells of the adenohypophysis in severe acute respiratory syndrome (SARS). *Biochem Cell Biol*. 2010;88:723–30.
90. Wilson L, Truong M, Barber A, Aoki T. Anterior pituitary and pituitary-dependent target organ function in men infected with the human immunodeficiency virus. *Metabolism*. 1996;45:738–46.
91. Huang Q, Kahn CR, Altindis E. Viral hormones: expanding dimensions in endocrinology. *Endocrinology*. 2019;160:2165–79.
92. Zeng W, Xing F, Ji Y, Yang S, Xu T, Huang S, Li C, Wu J, Cao L, Guo D. Evidence of infection of human embryonic stem cells by SARS-CoV-2. *Front Cell Infect Microbiol*. 2022;12:911313.
93. Ruck P, Marzusch K, Kaiserling E, Dietl J, Horny H, Handgretinger R, Vince G, Redman C. Role of cell adhesion molecules in implantation. *Fertil Steril*. 1995;63:1353–5.
94. Andersson EC, Christensen JP, Marker O, Thomsen A. Changes in cell adhesion molecule expression on T cells associated with systemic virus infection. *J Immunol* (Baltimore, MD: 1950). 1994, 152:1237–1245.
95. Jacobsen C, Plückerbaum N, Ssebyatika G, Beyer S, Mendes-Monteiro L, Wang J, Kropp KA, González-Motos V, Steinbrück L, Ritter B. Viral modulation of type II interferon increases T cell adhesion and virus spread. *Nat Commun*. 2024;15:5318.
96. Tabata T, Pettitt M, Zydek M, Fang-Hoover J, Larocque N, Tsuge M, Gormley M, Kauvar LM, Pereira L. Human cytomegalovirus infection interferes with the maintenance and differentiation of trophoblast progenitor cells of the human placenta. *J Virol*. 2015;89:5134–47.
97. Tabata T, McDonagh S, Kawakatsu H, Pereira L. Cytotrophoblasts infected with a pathogenic human cytomegalovirus strain dysregulate cell–matrix and cell–cell adhesion molecules: a quantitative analysis. *Placenta*. 2007;28:527–37.
98. Schleiss MR, Aronow BJ, Handwerker S. Cytomegalovirus infection of human syncytiotrophoblast cells strongly interferes with expression of genes involved in placental differentiation and tissue integrity. *Pediatr Res*. 2007;61:565–71.
99. Bortolotti D, Soffritti I, D'Accolti M, Gentili V, Di Luca D, Rizzo R, Caselli E. HHV-6A infection of endometrial epithelial cells affects miRNA expression and trophoblast cell attachment. *Reproductive Sci*. 2020;27:779–86.
100. Tsevat DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases and infertility. *Am J Obstet Gynecol*. 2017;216:1–9.
101. Liversedge N, Turner A, Horner P, Keay S, Jenkins J, Hull M. The influence of bacterial vaginosis on in-vitro fertilization and embryo implantation during assisted reproduction treatment. *Hum Reprod*. 1999;14:2411–5.
102. Isaguliantis M, Krasnyak S, Smirnova O, Colonna V, Apolikhin O, Buonaguro FM. Genetic instability and anti-HPV immune response as drivers of infertility associated with HPV infection. *Infect Agents Cancer*. 2021;16:29.
103. Hussien BM, Ahmadi G, Marzban H, Azar MEF, Sorayyayi S, Karampour R, Nahand JS, Hidayat HJ, Moghooei M. The role of HPV gene expression and selected cellular miRNAs in lung cancer development. *Microb Pathog*. 2021;150:104692.
104. Hemmat N, Bannazadeh Baghi H. Association of human papillomavirus infection and inflammation in cervical cancer. *Pathogens Disease*. 2019;77:ftz048.
105. Fernandes JV, Fernandes TAAM, De Azevedo JCV, Cobucci RNO, De Carvalho MGF, Andrade VS, De Araujo JMG. Link between chronic inflammation and human papillomavirus-induced carcinogenesis. *Oncol Lett*. 2015;9:1015–26.
106. Haghighi ZMS, Tabatabaei T, Rafigh M, Karampour R, Babei F, Amjad ZS, Payandeh M, Roozgar M, Bayat M, Doroudian M. Human papillomavirus maybe is a critical player in the regulation of chemoresistance related factors (P53, rb, TWIST, Bcl-2, Bcl-XL, c-IAP2, cytochrome C, and caspase 3) in breast cancer. *Pathology-Research Pract*. 2023;248:154653.
107. Khatami A, Nahand JS, Kiani SJ, Khoshmirisafa M, Moghooei M, Khanaliha K, Tavakoli A, Emtiazi N, Bokharai-Salim F. Human papilloma virus (HPV) and prostate cancer (PCa): the potential role of HPV gene expression and selected cellular miRNAs in PCa development. *Microb Pathog*. 2022;166:105503.
108. Nahand JS, Esghaei M, Monavari SH, Moghooei M, Kiani SJ, Mostafaei S, Mirzaei H, Bokharai-Salim F. The assessment of a possible link between HPV-mediated inflammation, apoptosis, and angiogenesis in prostate cancer. *Int Immunopharmacol*. 2020;88:106913.
109. Eppel W, Worda C, Frigo P, Ulm M, Kucera E, Czerwenka K. Human papillomavirus in the cervix and placenta. *Obstet Gynecol*. 2000;96:337–41.
110. Tapiuskaya N, Obédková K, Krikheli I, Tsechoeva L, Glushakov R. Persistent human papillomavirus infection in the genesis of reproductive losses. Prospects for therapy; 2021.
111. Zhuang B, Shang J, Yao Y. HLA-G: an important mediator of maternal-fetal immune-tolerance. *Front Immunol*. 2021;12:744324.
112. Hunt JS, Langat DK, McIntire RH, Morales PJ. The role of HLA-G in human pregnancy. *Reproductive Biology Endocrinol*. 2006;4:510.
113. Gazit E, Sherf M, Balbin E, Muratov A, Goldstein I, Loewenthal R. HLA-G expression is induced in Epstein-Barr virus–transformed B-cell lines by culture conditions. *Hum Immunol*. 2007;68:463–8.
114. Carbone L, Conforti A, Cariati F, Vallone R, Raffone A, Buonfantino C, Palese M, Mascia M, Capuzzo M, Esteves S. The negative impact of most relevant infections on fertility and assisted reproduction technology. *Minerva Obstet Gynecol*. 2021;74:83–106.
115. Pereira N, Kucharczyk KM, Estes JL, Gerber RS, Lekovich JP, Elias RT, Spandorfer SD. Human papillomavirus infection, infertility, and assisted reproductive outcomes. *J Pathogens*. 2015;2015:578423.
116. Zuo Z, Goel S, Carter JE. Association of cervical cytology and HPV DNA status during pregnancy with placental abnormalities and preterm birth. *Am J Clin Pathol*. 2011;136:260–5.
117. Gomez L, Ma Y, Ho C, McGrath C, Nelson D, Parry S. Placental infection with human papillomavirus is associated with spontaneous preterm delivery. *Hum Reprod*. 2008;23:709–15.
118. Chan PJ, Su BC, Kalugdan T, Seraj IM, Tredway DR, King A. Human papillomavirus gene sequences in washed human sperm deoxyribonucleic acid. *Fertil Steril*. 1994;61:982–5.
119. Rombaldi RL, Serafini EP, Mandelli J, Zimmermann E, Losquiavo KP. Transplacental transmission of human papillomavirus. *Virol J*. 2008;5:1–14.
120. Chan PJ, Kalugdan T, Su BC, Whitney EA, Perrott W, Tredway DR, King A. Sperm as a noninvasive gene delivery system for preimplantation embryos. *Fertil Steril*. 1995;63:1121–4.
121. Hong LJ, Oshiro BT, Chan PJ. HPV-16 exposed mouse embryos: a potential model for pregnancy wastage. *Arch Gynecol Obstet*. 2013;287:1093–7.
122. Hermonat P, Han L, Wendel P, Quirk J, Stern S, Lowery C, Rechten T. Human papillomavirus is more prevalent in first trimester spontaneously aborted products of conception compared to elective specimens. *Virus Genes*. 1997;14:13–7.
123. Henneberg AA, Patton WC, Jacobson JD, Chan PJ. Human papilloma virus DNA exposure and embryo survival is stage-specific. *J Assist Reprod Genet*. 2006;23:255–9.
124. Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K, Scheu S, Pfeffer K, Ware CF, Murphy TL. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. *Nat Immunol*. 2005;6:90–8.
125. Kawada J-i, Kimura H, Ito Y, Ando Y, Tanaka-Kitajima N, Hayakawa M, Nunoi H, Endo F, Morishima T. Evaluation of systemic inflammatory responses in neonates with herpes simplex virus infection. *J Infect Dis*. 2004;190:494–8.
126. Calandra T, Gerain J, Heumann D, Baumgartner J-D, Glauser MP, Group S-DJIS. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. *Am J Med*. 1991;91:23–9.
127. Felker AM, Nguyen P, Kaushic C. Primary HSV-2 infection in early pregnancy results in transplacental viral transmission and dose-dependent adverse pregnancy outcomes in a novel mouse model. *Viruses*. 2021;13:1929.
128. Kim ID, Chang HS, Hwang KJ. Herpes simplex virus 2 infection rate and necessity of screening during pregnancy: a clinical and seroepidemiologic study. *Yonsei Med J*. 2012;53:401.
129. Haider M, Rizvi M, Khan N, Malik A. Serological study of herpes virus infection in female patients with bad obstetric history. *Biology Med*. 2011;3:284–90.
130. Tsibizov A, Abdulmedzhidova A, Krasnopol'skaya K, Gadzhieva Z, Kushch A. Herpes simplex virus infection of human spermatozoa correlates with decreased frequency of blastocyst formation and frequency of embryo implantation during in vitro fertilization. *Russian J Dev Biology*. 2011;42:397–401.
131. Yueh YG, Yaworsky PJ, Kappen C. Herpes simplex virus transcriptional activator VP16 is detrimental to preimplantation development in mice. *Mol Reprod Dev*. 2000;55:37–46.
132. Carroll K, Hobden J, Miller S, Morse S, Mietzner T, Detrick B, Mitchell T, McKerrrow J, Sakanari J, Jawetz M. *Adelberg's Medical Microbiology, 27e*. McGraw-Hill Education New York, NY.; 2019.

133. Mostafaei S, Vahidi Manesh P, Sadri Nahand J, Nesaei A, Sorayyayi S, Abasabadi F, Mirzaei H, Etamadi A, O'Neill A, Donnelly SC. The role of Epstein-Barr virus-expressed genes in breast cancer development. *Breast J* 2020, 26.
134. Rousseau BA, Bhaduri-McIntosh S. Inflammation and Epstein-Barr Virus at the crossroads of multiple sclerosis and Post-acute Sequelae of COVID-19 infection. *Viruses*. 2023;15:949.
135. Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. *Adv Immunol*. 2003;81:199–252.
136. Amiot L, Le Friec G, Sebti Y, Drénou B, Pangault C, Guilloux V, Leleu X, Bernard M, Facon T, Fauchet R. HLA-G and lymphoproliferative disorders. *Seminars in cancer biology*. Elsevier; 2003. pp. 379–85.
137. Mandelboim O, Pazmany L, Davis D, Vales-Gomez M, Reyburn H, Rybalov B, Strominger J. Multiple receptors for HLA-G on human natural killer cells. *Proc Natl Acad Sci*. 1997;94:14666–70.
138. Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, Zaidi N, Azad NS, Laheru DA, Frampton GM. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. *JCI Insight* 2019, 4.
139. Guleria I, Khosroshahi A, Ansari MJ, Habicht A, Azuma M, Yagita H, Noelle RJ, Coyle A, Mellor AL, Khoury SJ. A critical role for the programmed death ligand 1 in fetomaternal tolerance. *J Exp Med*. 2005;202:231–7.
140. Prasad S, Hu S, Sheng WS, Chauhan P, Singh A, Lokensgard JR. The PD-1: PD-L1 pathway promotes development of brain-resident memory T cells following acute viral encephalitis. *J Neuroinflamm*. 2017;14:1–13.
141. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. *Nat Rev Microbiol*. 2021;19:759–73.
142. van Leeuwen EM, Remmerswaal E, Vossen M, Rowshani AT, Wertheim-van Dillen PM, van Lier RA, ten Berge IJ. Emergence of a CD4+ CD28– granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. *J Immunol*. 2004;173:1834–1841.
143. IS STCP, Repetitive DB. The size and phenotype of virus. T cell development in human cytomegalovirus infection:47.
144. Dons'koi BV, Tutchenko TM, Chernyshov VP, Stepaniuk KS. HCMV seropositivity is associated with specific proinflammatory immune phenotype in women with implantation failure. *Immunol Lett*. 2020;217:84–90.
145. Sherkat R, Meidani M, Zarabian H, Rezaei A, Gholamrezaei A. Seropositivity of cytomegalovirus in patients with recurrent pregnancy loss. *J Res Med Sciences: Official J Isfahan Univ Med Sci*. 2014;19:522.
146. Akunaeziri UA, Magaji AF, Anyaka C, Ocheke AN. Cytomegalovirus infection among women with recurrent miscarriages. *Trop J Obstet Gynecol*. 2021;38:128–38.
147. Hameed M, Aziz I. Detection of cytomegalovirus in Iraqi recurrent miscarriage women. *J Pharm Pharm Sci*. 2015;5:79–89.
148. Fisher S, Genbacev O, Maidji E, Pereira L. Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis. *J Virol*. 2000;74:6808–20.
149. Kleinman D, Sarov I, Insler V. Reactivation of cytomegalovirus in endometrial cells by estradiol. *Gynecol Obstet Invest*. 1986;21:136–43.
150. Zerbini M, Musiani M, Carpi C, Falcieri E. Productive and abortive replication of human cytomegalovirus at different environmental pH values. *Arch Virol*. 1982;72:127–31.
151. Iversen MB, Paludan SR, Holm CK. Vaginal HSV-2 infection and tissue analysis. *Bio-protocol*. 2017;7:e2383–2383.
152. Ye L, Qian Y, Yu W, Guo G, Wang H, Xue X. Functional profile of human cytomegalovirus genes and their associated diseases: a review. *Front Microbiol*. 2020;11:2104.
153. Ablashi D, Agut H, Alvarez-Lafuente R, Clark DA, Dewhurst S, DiLuca D, Flaman L, Frenkel N, Gallo R, Gompels UA. Classification of HHV-6A and HHV-6B as distinct viruses. *Arch Virol*. 2014;159:863–70.
154. Marci R, Gentili V, Bortolotti D, Lo Monte G, Caselli E, Bolzani S, Rotola A, Di Luca D, Rizzo R. Presence of HHV-6A in endometrial epithelial cells from women with primary unexplained infertility. *PLoS ONE*. 2016;11:e0158304.
155. Okuno T, Oishi H, Hayashi K, Nonogaki M, Tanaka K, Yamaniishi K. Human herpesviruses 6 and 7 in cervixes of pregnant women. *J Clin Microbiol*. 1995;33:1968–70.
156. Baillargeon J, Piper J, Leach CT. Epidemiology of human herpesvirus 6 (HHV-6) infection in pregnant and nonpregnant women. *J Clin Virol*. 2000;16:149–57.
157. MAEDA T, OKUNO T, HAYASHI K, NAGATA M, UEDA M, TERASHIMA K, KAWASHIMA T, MIYAMOTO H, MORI T, YAMADA Y. Outcomes of infants whose mothers are positive for human herpesvirus-6 DNA within the genital tract in early gestation. *Pediatr Int*. 1997;39:653–7.
158. Mesechkova K, Kavrakova A, Georgieva B, Sigridov I, Mitev V, Todorova A. Non-invasive Diagnostics of Reproductive Failure with infectious etiology on menstrual tissue. *Acta Med Bulg*. 2023;50:5–10.
159. Mesechkova K, Kavrakova A, Georgieva B, Sigridov I, Miteva A, Mitev V, Todorova A. Bacterial and viral pathogens implicated in female reproductive failure investigated on menstrual blood. In *Proceedings of the Bulgarian Academy of Sciences*. 2023: 394–406.
160. Coulam CB, Bilal M, Salazar Garcia MD, Katukurundage D, Elazzamy H, Fernandez EF, Kwak-Kim J, Beaman K, Dambaeva SV. Prevalence of HHV-6 in endometrium from women with recurrent implantation failure. *Am J Reprod Immunol*. 2018;80:e12862.
161. Vicetti Miguel RD, Sheridan BS, Harvey SA, Schreiner RS, Hendricks RL, Cherpes TL. 17- β estradiol promotion of herpes simplex virus type 1 reactivation is estrogen receptor dependent. *J Virol*. 2010;84:565–72.
162. Ozkan ZS, Devenci D, Kumbak B, Simsek M, Ilhan F, Sekercioglu S, Sapmaz E. What is the impact of Th1/Th2 ratio, SOCS3, IL17, and IL35 levels in unexplained infertility? *J Reprod Immunol*. 2014;103:53–8.
163. Li C, Goodrich J, Yang X. Interferon-gamma (IFN- γ) regulates production of IL-10 and IL-12 in human herpesvirus-6 (HHV-6)-infected monocyte/macrophage lineage. *Clin Experimental Immunol*. 1997;109:421–5.
164. Arena A, Liberto M, Iannello D, Capozza A, Foca A. Altered cytokine production after human herpes virus type 6 infection. *new Microbiol*. 1999;22:293–300.
165. Ando Y, Kakimoto K, Ekuni Y, Ichijo M. HHV-6 infection during pregnancy and spontaneous abortion. *Lancet*. 1992;340:1289.
166. Drago F, Broccolo F, Javor S, Drago F, Rebora A, Parodi A. Evidence of human herpesvirus-6 and-7 reactivation in miscarriage women with pityriasis rosea. *J Am Acad Dermatol*. 2014;71:198–9.
167. Angius F, Ingianni A, Pompei R. Human herpesvirus 8 and host-cell Interaction: long-lasting physiological modifications, inflammation and related chronic diseases. *Microorganisms*. 2020;8:388.
168. Di Stefano M, Calabro ML, Di Gangi IM, Cantatore S, Barbierato M, Bergamo E, Kfutwah AJ, Neri M, Chieco-Bianchi L, Greco P. In vitro and in vivo human herpesvirus 8 infection of placenta. *PLoS ONE*. 2008;3:e4073.
169. Jiang X-F, Tang Q-L, Zou Y, Xu L, Zeng H, Chi C, Jiang J-R, Zhang B-Z. Does HBV infection increase risk of endometrial carcinoma? *Asian Pac J Cancer Prev*. 2014;15:713–6.
170. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. *J Gen Virol*. 2006;87:1439–49.
171. Zhong S, Zhang T, Tang L, Li Y. Cytokines and chemokines in HBV infection. *Front Mol Biosci*. 2021;8:805625.
172. Song H, Tan G, Yang Y, Cui A, Li H, Li T, Wu Z, Yang M, Lv G, Chi X. Hepatitis B virus-induced imbalance of inflammatory and antiviral signaling by differential phosphorylation of STAT1 in human monocytes. *J Immunol*. 2019;202:2266–75.
173. Zlotkowska A, Andronowska A. Chemokines as the modulators of endometrial epithelial cells remodelling. *Sci Rep*. 2019;9:12968.
174. Zhuo J-Y, Lu D, Lin Z-Y, Cen B-N, Wei X-Y, Xie H-Y, Zheng S-S, Xu X. CC motif chemokine ligand 16 inhibits the progression of liver cirrhosis via inactivating hepatic stellate cells. *Hepatobiliary Pancreat Dis Int*. 2020;19:440–8.
175. Li L, Wang L, Huang C, Diao L, Zhang Y, Zhang X, Xu J, Zeng Y. Chronic hepatitis B infection alters peripheral immune response in women with reproductive failure. *Am J Reprod Immunol*. 2019;81:e13083.
176. Farsimadan M, Motamedifar M. The effects of human immunodeficiency virus, human papillomavirus, herpes simplex virus-1 and-2, human herpesvirus-6 and-8, cytomegalovirus, and hepatitis B and C virus on female fertility and pregnancy. *Br J Biomed Sci*. 2021;78:1–11.
177. Cui A-M, Cheng X-Y, Shao J-G, Li H-B, Wang X-L, Shen Y, Mao L-J, Zhang S, Liu H-Y, Zhang L. Maternal hepatitis B virus carrier status and pregnancy outcomes: a prospective cohort study. *BMC Pregnancy Childbirth*. 2016;16:1–8.
178. Lam PM, Suen SH, Lao TT, Cheung LP, Leung TY, Haines C. Hepatitis B infection and outcomes of in vitro fertilization and embryo transfer treatment. *Fertil Steril*. 2010;93:480–5.
179. Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. *Nat Rev Microbiol*. 2022;20:270–84.
180. Wong JP, Viswanathan S, Wang M, Sun L-Q, Clark GC, D'Elia RV. Current and future developments in the treatment of virus-induced hypercytokinemia. *Future Med Chem*. 2017;9:169–78.
181. Fajgenbaum DC, June CH. Cytokine storm. *N Engl J Med*. 2020;383:2255–73.

182. Henarejos-Castillo I, Sebastian-Leon P, Devesa-Peiro A, Pellicer A, Diaz-Gimeno P. SARS-CoV-2 infection risk assessment in the endometrium: viral infection-related gene expression across the menstrual cycle. *Fertil Steril*. 2020;114:223–32.
183. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. Structural basis of receptor recognition by SARS-CoV-2. *Nature*. 2020;581:221–4.
184. Haouzi D, Entezami F, Brouillet S, Barry F, Gala A, Ferrieres-Hoa A, Tal A, Hamamah S. O-141 mapping of SARS-CoV-2-associated receptors and proteases mRNA in human endometrium during natural and stimulated cycles. *Hum Reprod*. 2021;36:deab127.
185. Qi R, Guan R, Cai S, Xu M, Yang W-j, Wang CC. Comprehensive molecular expression profiling of SARS-CoV-associated factors in the endometrium across the menstrual cycle and elevated susceptibility in women with recurrent pregnancy loss. *Front Genet*. 2023;14:1246725.
186. Xue Y, Xiong Y, Cheng X, Li K. Impact of SARS-CoV-2 infection on clinical outcomes of in vitro fertilization treatments: a systematic review and meta-analysis. *Front Endocrinol*. 2023;14:1233986.
187. Rabbani M, Rogers P. Role of vascular endothelial growth factor in endometrial vascular events before implantation in rats. *Reprod (Cambridge England)*. 2001;122:85–90.
188. Zhang J, Wang L, Cai L, Cao Y, Duan E. The expression and function of VEGF at embryo implantation window in the mouse. *Chin Sci Bull*. 2001;46:409–11.
189. Guo H, Yin M, Liu Y, Wang B, Lin J, Zhu Q. COVID-19 infection after oocyte retrieval did not have detrimental effects on embryo implantation for frozen embryo transfer. *J Med Virol*. 2023;95:e29054.
190. Baud D, Gubler DJ, Schaub B, Lanteri MC, Musso D. An update on Zika virus infection. *Lancet*. 2017;390:2099–109.
191. Harsh S, Fu Y, Kenney E, Han Z, Eleftherianos I. Zika virus non-structural protein NS4A restricts eye growth in *Drosophila* through regulation of JAK/STAT signaling. *Dis Models Mech* 2020, 13.
192. Tan L, Lacko LA, Zhou T, Tomoiaga D, Hurtado R, Zhang T, Sevilla A, Zhong A, Mason CE, Noggle S. Pre- and peri-implantation Zika virus infection impairs fetal development by targeting trophoblast cells. *Nat Commun*. 2019;10:4155.
193. Li Y, Zhu H, Klausen C, Peng B, Leung PC. Vascular endothelial growth factor-A (VEGF-A) mediates activin A-induced human trophoblast endothelial-like tube formation. *Endocrinology*. 2015;156:4257–68.
194. Yamada M, Kim S, Egashira K, Takeya M, Ikeda T, Mimura O, Iwano H. Molecular mechanism and role of endothelial monocyte chemoattractant protein-1 induction by vascular endothelial growth factor. *Arterioscler Thromb Vasc Biol*. 2003;23:1996–2001.
195. Nunes P, Nogueira R, Coelho J, Rodrigues F, Salomão N, José C, de Carvalho J, Rabelo K, de Azeredo E. Basilio-de-Oliveira R: a stillborn multiple organs' investigation from a maternal DENV-4 infection: histopathological and inflammatory mediators characterization. *Viruses*. 2019;11:319.
196. Tan L, Lacko LA, Zhou T, Tomoiaga D, Hurtado R, Zhang T, Sevilla A, Zhong A, Mason CE, Noggle S, et al. Pre- and peri-implantation Zika virus infection impairs fetal development by targeting trophoblast cells. *Nat Commun*. 2019;10:4155.
197. Block LN, Aliota MT, Friedrich TC, Schotzko ML, Mean KD, Wiepzig GJ, Golos TG, Schmidt JK. Embryotoxic impact of Zika virus in a rhesus macaque in vitro implantation model. *Biol Reprod*. 2020;102:806–16.
198. Hammond SM. An overview of microRNAs. *Adv Drug Deliv Rev*. 2015;87:3–14.
199. Shang R, Lee S, Senavirathne G, Lai EC. microRNAs in action: biogenesis, function and regulation. *Nat Rev Genet*. 2023;24:816–33.
200. Kirstein N, Dokaneheifard S, Cingaram PR, Valencia MG, Beckedorff F, Gomes Dos Santos H, Blumenthal E, Tayari MM, Gaidosh GS, Shiekhattar R. The integrator complex regulates microRNA abundance through RISC loading. *Sci Adv*. 2023;9:eadf0597.
201. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O, Kim S. The nuclear RNase III Drosha initiates microRNA processing. *Nature*. 2003;425:415–9.
202. Rosca A, Anton G, Botezatu A, Temereanca A, Ene L, Achim C, Ruta S. miR-29a associates with Viro-immunological markers of HIV infection in treatment experienced patients. *J Med Virol*. 2016;88:2132–7.
203. Skalsky RL, Cullen BR. Viruses, microRNAs, and host interactions. *Annu Rev Microbiol*. 2010;64:123–41.
204. Cullen BR. Viruses and microRNAs. *Nat Genet*. 2006;38:S25–30.
205. Gottwein E. Roles of microRNAs in the life cycles of mammalian viruses. *Intrinsic Immunol* 2013;201–27.
206. Shariati MBH, Niknafs B, Seghinsara AM, Shokrzadeh N, Alivand MR. Administration of dexamethasone disrupts endometrial receptivity by alteration of expression of miRNA 223, 200a, LIF, Muc1, SGK1, and ENaC via the ERK1/2-mTOR pathway. *J Cell Physiol*. 2019;234:19629–39.
207. Goharitaban S, Abedelahi A, Hamdi K, Khazaei M, Esmaeilvand M, Niknafs B. Role of endometrial microRNAs in repeated implantation failure (mini-review). *Front Cell Dev Biol*. 2022;10:936173.
208. Paul AB, Sadek ST, Mahesan AM. The role of microRNAs in human embryo implantation: a review. *J Assist Reprod Genet*. 2019;36:179–87.
209. Reza AMMT, Choi YJ, Han SG, Song H, Park C, Hong K, Kim JH. Roles of microRNAs in mammalian reproduction: from the commitment of germ cells to peri-implantation embryos. *Biol Rev*. 2019;94:415–38.
210. Revel A, Achache H, Stevens J, Smith Y, Reich R. MicroRNAs are associated with human embryo implantation defects. *Hum Reprod*. 2011;26:2830–40.
211. Chang L, Yuan Z, Shi H, Bian Y, Guo R. miR-145 targets the SOX11 3'UTR to suppress endometrial cancer growth. *Am J cancer Res*. 2017;7:2305.
212. Sirohi VK, Gupta K, Kapoor R, Dwivedi A. MicroRNA-145 targets Smad1 in endometrial stromal cells and regulates decidualization in rat. *J Mol Med*. 2019;97:509–22.
213. Liu X, Zhao H, Li W, Bao H, Qu Q, Ma D. Up-regulation of miR-145 may contribute to repeated implantation failure after IVF-embryo transfer by targeting PAI-1. *Reprod Biomed Online*. 2020;40:627–36.
214. Kang Y-J, Lees M, Matthews LC, Kimber SJ, Forbes K, Aplin JD. miR-145 suppresses embryo-epithelial juxtacrine communication at implantation by modulating maternal IGF1R. *J Cell Sci*. 2015;128:804–14.
215. Nazarian H, Novin MG, Khaleghi S, Habibi B. Small non-coding RNAs in embryonic pre-implantation. *Curr Mol Med*. 2022;22:287–99.
216. Pinho JD, Silva GEB, Júnior AALT, de Castro Belfort MR, Mendes JMM, Calixto JRR, Nogueira LR, Burbano RR, Khayat AS. Downregulation of miR-145 is associated with perineural invasion in penile carcinoma. *Transl Androl Urol*. 2021;10:2019.
217. Yu F, Liu J, Dong W, Xie J, Zhao X. The diagnostic value of miR-145 and miR-205 in patients with cervical cancer. *Am J Translational Res*. 2021;13:1825.
218. Lu H, He Y, Lin L, Qi Z, Ma L, Li L, Su Y. Long non-coding RNA MALAT1 modulates radiosensitivity of HR-HPV+ cervical cancer via sponging miR-145. *Tumor Biology*. 2016;37:1683–91.
219. Gunasekharan V, Laimins LA. Human papillomaviruses modulate microRNA 145 expression to directly control genome amplification. *J Virol*. 2013;87:6037–43.
220. Heawchaiyaphum C, Ekalaksananan T, Patarapadungkit N, Worawichawong S, Pientong C. Epstein-Barr virus infection alone or jointly with human papillomavirus associates with down-regulation of miR-145 in oral squamous-cell carcinoma. *Microorganisms*. 2021;9:2496.
221. Okoye JO, Ngokere AA, Onyenekwe CC, Omotuyi O, Dada DI. Epstein-Barr virus, human papillomavirus and herpes simplex virus 2 co-presence severely dysregulates miRNA expression. *Afr J Lab Med*. 2021;10:1–10.
222. Yu Z, Wang J, Nan F, Shi W, Zhang X, Jiang S, Wang B. Human Cytomegalovirus Induced aberrant expression of non-coding RNAs. *Front Microbiol*. 2022;13:918213.
223. Xiong J, Yu D, Wei N, Fu H, Cai T, Huang Y, Wu C, Zheng X, Du Q, Lin D. An estrogen receptor α suppressor, microRNA-22, is downregulated in estrogen receptor α -positive human breast cancer cell lines and clinical samples. *FEBS J*. 2010;277:1684–94.
224. Wongjampa W, Ekalaksananan T, Chopitt P, Chuerduangphui J, Kleeboak P, Patarapadungkit N, Pientong C. Suppression of miR-22, a tumor suppressor in cervical cancer, by human papillomavirus 16 E6 via a p53/miR-22/HDAC6 pathway. *PLoS ONE*. 2018;13:e0206644.
225. Hu Y, Setayesh T, Vaziri F, Wu X, Hwang ST, Chen X, Wan Y-JY. miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism. *Mol Ther*. 2023;31:1829–45.
226. Tian J, Wang W, Zhu J, Zhuang Y, Qi C, Cai Z, Yan W, Lu W, Shang A. Histone Methyltransferase SETDB1 Promotes Immune Evasion in Colorectal Cancer via FOSB-Mediated Downregulation of MicroRNA-22 through BATF3/PD-L1 Pathway. *J Immunol Res*. 2022;4012920.
227. Lu W, You R, Yuan X, Yang T, Samuel EL, Marcano DC, Sikkema WK, Tour JM, Rodriguez A, Kheradmand F. The microRNA miR-22 inhibits the histone deacetylase HDAC4 to promote TH17 cell-dependent emphysema. *Nat Immunol*. 2015;16:1185–94.
228. Grewal S, Carver JG, Ridley AJ, Mardon HJ. Implantation of the human embryo requires Rac1-dependent endometrial stromal cell migration. *Proceedings of the National Academy of Sciences*. 2008;105:16189–16194.
229. Ma H-L, Gong F, Tang Y, Li X, Li X, Yang X, Lu G. Inhibition of endometrial Tiam1/Rac1 signals induced by miR-22 up-regulation leads to the failure of

- embryo implantation during the implantation window in pregnant mice. *Biol Reprod.* 2015;92:152. 151–113.
230. Kwon A-Y, Jeong J-Y, Park H, Hwang S, Kim G, Kang H, Heo J-H, Lee HJ, Kim T-H, An HJ. Mir-22-3p and miR-30e-5p are associated with prognosis in cervical squamous cell carcinoma. *Int J Mol Sci.* 2022;23:5623.
231. Khosravi M, Behboudi E, Razavi-Nikoo H, Tabarraei A. Hepatitis B virus X protein induces expression changes of miR-21, miR-22, miR-122, miR-132, and miR-222 in Huh-7 cell line. *Arch Razi Inst.* 2024;79:111–9.
232. Shi C, Xu X. MicroRNA-22 is down-regulated in hepatitis B virus-related hepatocellular carcinoma. *Biomed Pharmacother.* 2013;67:375–80.
233. Bell-Hensley A, Das S, McAlinden A. The miR-181 family: wide-ranging pathophysiological effects on cell fate and function. *J Cell Physiol.* 2023;238:698–713.
234. Li Q-J, Chau J, Ebert PJ, Sylvester G, Min H, Liu G, Braich R, Manoharan M, Soutschek J, Skare P. miR-181a is an intrinsic modulator of T cell sensitivity and selection. *Cell.* 2007;129:147–61.
235. Chu B, Zhong L, Dou S, Wang J, Li J, Wang M, Shi Q, Mei Y, Wu M. miRNA-181 regulates embryo implantation in mice through targeting leukemia inhibitory factor. *J Mol Cell Biol.* 2015;7:12–22.
236. Troy PJ, Daftary GS, Bagot CN, Taylor HS. Transcriptional repression of peri-implantation EMX2 expression in mammalian reproduction by HOXA10. *Mol Cell Biol.* 2003.
237. Aghajanova L, Altmäe S, Bjuresten K, Hovatta O, Landgren B-M, Stavreus-Evers A. Disturbances in the LIF pathway in the endometrium among women with unexplained infertility. *Fertil Steril.* 2009;91:2602–10.
238. Zhang Q, Zhang H, Jiang Y, Xue B, Diao Z, Ding L, Zhen X, Sun H, Yan G, Hu Y. MicroRNA-181a is involved in the regulation of human endometrial stromal cell decidualization by inhibiting Krüppel-like factor 12. *Reproductive Biology Endocrinol.* 2015;13:1–9.
239. Lee SH, Lee C-R, Rigas NK, Kim RH, Kang MK, Park N-H, Shin K-H. Human papillomavirus 16 (HPV16) enhances tumor growth and cancer stemness of HPV-negative oral/oropharyngeal squamous cell carcinoma cells via miR-181 regulation. *Papillomavirus Res.* 2015;1:116–25.
240. Gao L, Ai J, Xie Z, Zhou C, Liu C, Zhang H, Shen K. Dynamic expression of viral and cellular microRNAs in infectious Mononucleosis caused by primary Epstein-Barr virus infection in children. *Virology.* 2015;12:1–11.
241. Zou C, Li Y, Cao Y, Zhang J, Jiang J, Sheng Y, Wang S, Huang A, Tang H. Up-regulated MicroRNA-181a induces carcinogenesis in hepatitis B virus-related hepatocellular carcinoma by targeting E2F5. *BMC Cancer.* 2014;14:1–9.
242. Cuman C, Van Sinderen M, Gantier MP, Rainczuk K, Sorby K, Rombauts L, Osianlis T, Dimitriadis E. Human blastocyst secreted microRNA regulate endometrial epithelial cell adhesion. *EBioMedicine.* 2015;2:1528–35.
243. Hoffman Y, Bublik D, Pilpel Y, Oren M. miR-661 downregulates both Mdm2 and Mdm4 to activate p53. *Cell Death Differ.* 2014;21:302–9.
244. Silva JM, Deus AJ, Vale AA, Azevedo-Santos APS, Nogueira L, Laus AC, Sussuchi L, Reis RM, Birbrair A, Khayat AS. MIR-376A-2-5P as a potential prognostic marker for advanced penile squamous cell carcinomas through HPV-dependent pathways. *Am J Cancer Res.* 2023;13:5466.
245. Martínez-Noël G, Szajner P, Kramer RE, Boyland KA, Sheikh A, Smith JA, Howley PM. Identification of microRNAs that stabilize p53 in HPV-positive cancer cells. *bioRxiv* 2020:2020.2009. 2021.305946.
246. Sivasudhan E, Blake N, Lu Z, Meng J, Rong R. Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma: a comprehensive review. *Cells.* 2022;11:741.
247. Wang Z, Wu Z, Huang P. The function of miRNAs in hepatocarcinogenesis induced by hepatitis B virus X protein. *Oncol Rep.* 2017;38:652–64.
248. Balasenthil S, Broaddus RR, Kumar R. Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. *Hum Pathol.* 2006;37:656–61.
249. Mao L, Liu S, Hu L, Jia L, Wang H, Guo M, Chen C, Liu Y, Xu L. miR-30 family: a promising regulator in development and disease. *BioMed Res Int.* 2018;9623412.
250. Kresowik JD, Devor EJ, Van Voorhis BJ, Leslie KK. MicroRNA-31 is significantly elevated in both human endometrium and serum during the window of implantation: a potential biomarker for optimum receptivity. *Biol Reprod.* 2014;91(17):11–6.
251. Parks J, McCallie B, Strieby A, McReynolds S, Schoolcraft W, Katz-Jaffe M. Non-invasive omics analysis of endometrial secretions 24 hours prior to frozen embryo transfer is predictive of implantation outcome. *Fertil Steril.* 2014;102:e134–5.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.